
Szoboszlai Holding ApS

CVR-no.: 43954873

Klosterparkvej 6 2 th
4400 Kalundborg

Annual report
1 April 2024 - 31 March 2025

**The annual report has been presented and
approved on the company's general meeting
the**

14/09/2025

Patrik Szoboszlai
Chairman of general meeting

Content

Company informations

Company informations

Management's Review

Management's Review

Financial statement

Accounting Policies

Income statement

Balance sheet

Disclosures

Company information

**Reporting
company**

Szoboszlai Holding ApS

Klosterparkvej 6 2 th
4400 Kalundborg

Phone number: 50285875

e-mail: szoboszlai.c.patrik@gmail.com

CVR-no.: 43954873

Reporting
period: 01/04/2024 - 31/03/2025

Management's Review

Main activities

Szoboszlai Holding ApS hold Milky Way Biotech ApS and involved in no other activities.

Development in activities and financial conditions

The financial result has met expectations as no gains or investments have been expect along the fiscal year 2025/24. The only cost Szoboszlai Holding ApS had to cover were Business Bank Account Fees, charged by DanskeBank.

Events after the end of the financial year

The company hold by Szoboszlai Holding ApS, Milky Way Biotech ApS, and Szoboszlai Holding ApS are both in scope to undergo dissolution along the coming month. The reason for dissolution is the fact that the project results of Milky Way Biotech ApS does not allow the project to continue (research results from in-vitro laboratory studies). For that reason Szoboszlai Holding ApS had no reason to be capt registered and kept active.

Management considers the conditions for opting out of audit to be met.

Accounting Policies

The annual report has been prepared in accordance with the regulation applying to Reporting class B.
No changes in accounting policies.

Income statement 1 Apr 2024 - 31 Mar 2025

	Disclosure	2024/25 DKK	2023/24 DKK
Revenue		0	0
External expenses	1	1,188	0
Gross Result		1,188	0
Gross profit (loss)		0	0
Employee expense	2	0	0
Wages and salaries			0
Post-employment benefit expense			0
Social security contributions			0
Other employee expense			0
Depreciation, amortisation expense and impairment losses of property, plant and equipment and intangible assets		0	0
Profit (loss) from ordinary operating activities		1,188	0
Income from other investments and receivables that are fixed assets	3	0	0
Other finance income	4	0	40,000
Impairment of financial assets		0	0
Other finance expenses		0	-3,170
Profit (loss) from ordinary activities before tax		1,188	36,830
Tax expense		0	0
Profit (loss)		1,188	36,830
Proposed distribution of results			
Proposed dividend recognised in equity		0	0
Reserve for net revaluation according to equity method		0	0
Retained earnings		1,188	36,830
Proposed distribution of profit (loss)		1,188	36,830

Balance sheet 31 March 2025

Assets

	Disclosure	2024/25	2023/24
		DKK	DKK
Goodwill		0	0
Intangible assets		0	0
Land and buildings		0	0
Plant and machinery		0	0
Fixtures, fittings, tools and equipment		0	0
Right of use assets		0	0
Property, plant and equipment		0	0
Investments in group enterprises		0	20,000
Investments in associates		0	0
Participating interests		0	0
Other investments		0	20,000
Contract assets		0	0
Investments		0	40,000
Total non-current assets		0	40,000
Raw materials and consumables		0	0
Manufactured goods and goods for resale		0	0
Inventories		0	0
Trade receivables		0	0
Contract work in progress		0	0
Receivables from group enterprises		0	0
Receivables from associates		0	0
Receivables from participating interests		0	0
Tax receivables		0	0
Receivables from vat and duties		0	0
Other receivables		0	0
Contract assets		0	0
Receivables		0	0
Other investments		0	0
Investments		0	0
Cash and cash equivalents		0	16,830
Current assets		0	16,830
TOTAL ASSETS		0	56,830

Balance sheet 31 March 2025

Liabilities and equity

	Disclosure	2024/25	2023/24
		DKK	DKK
Contributed capital		0	40,000
Other reserves		0	0
Retained earnings		0	16,830
Proposed dividend		0	0
Total equity		0	56,830
Provisions for deferred tax		0	0
Provisions, gross		0	0
Mortgage debt		0	0
Debt to banks		0	0
Tax payables		0	0
Contract liabilities		0	0
Long-term liabilities other than provisions, gross		0	0
Mortgage debt		0	0
Debt to banks		0	0
Trade payables		0	0
Payables to group enterprises		0	0
Payables to associates		0	0
Payables to participating interests		0	0
Tax payables		0	0
Payables to vat and duties		0	0
Other payables, including tax payables, liabilities other than provisions		0	0
Proposed dividend for report period		0	0
Contract liabilities		0	0
Short-term liabilities other than provisions, gross		0	0
Liabilities other than provisions, gross		0	0
LIABILITIES AND EQUITY, GROSS		0	56,830

Disclosures

1. External expenses

Bank fees (Danske Bank) for the year: 1,188 DKK.

2. Employee expense

The holding ApS has no employee	2024/25	2023/24
	DKK	DKK
Wages and salaries	xxx.xxx	xxxxx
Post employment benefit expense	xxx.xxx	xxxxx
Social security contributions	xxx.xxx	xxxxx
	<u>xxx.xxx</u>	<u>xxxxx</u>

3. Income from other investments and receivables that are fixed assets

No income for Szoboszlai Holding ApS.

4. Other finance income

For the fiscal year 2023/2024, 40.000 DKK stands for the amount that was used to incorporate Szoboszlai Holding ApS, from which 20.000 DKK was transferred to incorporate Milky Way Biotech ApS.

5. Information on average number of employees

	2024/25
Average number of employees	0

Szoboszlai Holding ApS has no employee and have never been in scope of receiving financial gains along the previous fiscal years, and the current one. For the same reason, it have never been in scope to register employee under Szoboszlai Holding ApS.